2026-04-13T13:12:02Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/109352025-10-24T10:38:15Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Socie, Gerard
author
Barlev, Arie
author
Sanz, Jaime
author
Garcia Cadenas, Irene
author
chevallier, patrice
author
Barba, Pere
2025-10-24T10:38:15Z
2025-10-24T10:38:15Z
2024-01-30T08:36:13Z2024-01-30T08:36:13Z2024-01
http://hdl.handle.net/11351/10935
Enfermedad linfoproliferativa; Virus de Epstein-BarrMalaltia limfoproliferativa; Virus d'Epstein-BarrLymphoproliferative disease; Epstein-Barr virusEpstein–Barr virus-positive (EBV+) post-transplant lymphoproliferative disease (PTLD) is an ultra-rare and aggressive condition that may occur following allogeneic hematopoietic cell transplant (HCT) due to immunosuppression. Approximately half of EBV+ PTLD cases are relapsed or refractory (R/R) to initial rituximab-containing therapy. There are limited treatment options and no standard of care for patients with R/R EBV+ PTLD, and little is known about their treatment history and outcomes. We performed a multinational, multicenter, retrospective chart review of patients with R/R EBV+ PTLD following HCT to describe patients’ demographic and disease characteristics, treatment history, and overall survival (OS) from rituximab failure. Among 81 patients who received initial treatment with rituximab as monotherapy (84.0%) or in combination with chemotherapy (16.0%), median time from HCT to PTLD diagnosis was 3.0 months and median OS was 0.7 months. Thirty-six patients received a subsequent line of treatment. The most frequent causes of death were PTLD (56.8%), graft-versus-host disease (13.5%) and treatment-related mortality (10.8%). In multivariate analysis, early PTLD onset and lack of response to initial treatment were associated with mortality. This real-world study demonstrates that the prognosis of patients with R/R EBV+ PTLD following HCT remains poor, highlighting the urgent unmet medical need in this population.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Trastorns limfoproliferatius
Cèl·lules mare hematopoètiques - Trasplantació
Infeccions per virus d'Epstein-Barr
DISEASES::Immune System Diseases::Immunoproliferative Disorders::Lymphoproliferative Disorders
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation
DISEASES::Virus Diseases::DNA Virus Infections::Herpesviridae Infections::Epstein-Barr Virus Infections
ENFERMEDADES::enfermedades del sistema inmune::trastornos inmunoprolifertivos::trastornos linfoproliferativos
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre hematopoyéticas
ENFERMEDADES::virosis::infecciones por virus ADN::infecciones por Herpesviridae::infecciones por virus de Epstein-Barr
Outcomes for patients with EBV-positive PTLD post-allogeneic HCT after failure of rituximab-containing therapy
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion